Question-and-Answer Session
Operator
(Operator instructions) Your first question comes from Mike Weinstein with JP Morgan.
Mike Weinstein – JP Morgan
Let me start with a couple areas and forgive me it’s been a long day and a long month. So I know you’ve covered some of this, but I just want to make sure I understood. First, with some of the non-EP initiatives that you have underway and some of the opportunities there, I heard your comments and I want to make sure I understand what your strategy is with regard to AorTx, with regard to some of these other vascular and non-vascular opportunities, to what degree you’re going to look the partner up these opportunities and should we expect to hear anything on that front in the next three months, six months whatever?
Fred Moll
Yes, so many go through and we spent a lot time on the endovascular portion and excited that is nearer term opportunity where as I said, we did our first human, we’re going to do more humans. We are building a story in vascular surgery, that we’re really excited about and as I say, that can be our contributor to revenues next year in a fairly significant way. The valve opportunity is obviously a longer term thing, we’ve made some good progress with understanding and characterizing our valve and what’s exciting about that the percutaneous valve market is: (A) it’s going quickly and (B) to great degree I would characterize it and not everybody would agree with this, but I think there is great evidence that it’s really not about the valve per sake, it’s about delivering our procedure so that is able to reduce to as low as possible the risk associated we delivering in setup of eight valve.
All these valves, which we know are pretty similar in their function and so we believe that now concentrating rather than spending millions of dollars on developing our own valve by ourselves, we think there is a great opportunity to partner and develop the valve or whatever valve that is in conjunction with our delivery system, because we believe the delivery system is the key to widespread adoption of these procedures and really driving the Hansen opportunity.
Mike Weinstein – JP Morgan
Just to be clear here so are you at point in dialogue with strategic partners on, whether it to be trans-catheter valve placement or some of these other opportunities?
- To read the full transcript on Seeking Alpha, click here »
